Skip to main
LENZ
LENZ logo

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics Inc has successfully completed a comprehensive clinical program consisting of three Phase 3 trials, known as the CLARITY program, which demonstrated strong efficacy and a clean safety profile, establishing a potentially market-leading position in the treatment of presbyopia. The company is projected to achieve profitability by 2028, indicating a positive financial outlook and strategic growth potential. Given the significant market demand for treatments that address age-related vision deterioration, LENZ is well-positioned to capitalize on this opportunity as it moves toward commercialization.

Bears say

LENZ Therapeutics Inc faces substantial risks that contribute to a negative outlook, primarily due to a lack of diversification in its product pipeline, with LNZ100 being the sole focus. The company may also encounter significant commercial challenges, particularly in changing consumer behavior related to presbyopia treatment, which can adversely affect revenue and earnings expectations. Furthermore, the presence of competitive dynamics in the ophthalmic market and potential generic challenges to LNZ100's intellectual property add to the uncertainty surrounding LENZ's future financial performance.

LENZ has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 4 analysts, LENZ has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.